Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Phase II Clinical Study of Cadonilimab Combination With Chemotherapy With or Without the Anti-CD47 Antibody AK117 Neoadjuvant/Adjuvant Therapy for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Weifeng Song, MD
- Phone Number: +86(0760)89873999
- Email: clinicaltrials@akesobio.com
Study Contact Backup
- Name: Han Liang, MD
Study Locations
-
-
-
Tianjin, China
- Recruiting
- Tianjin Provincial Tumor Hospital
-
Contact:
- Han Liang, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be able and willing to provide written informed consent.
- 18 to 75 years old.
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Has a histologically confirmed diagnosis of Gastric or Gastroesophageal Junction Adenocarcinoma(G/GEJ).
- Has Stage T3-4N+M0 G/GEJ (American Joint Committee on Cancer [AJCC])
- Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
- Has adequate organ function.
Exclusion Criteria:
- Are there suspected metastases or locally advanced, unresectable disease, regardless of disease stage.
- Is currently participating in a study of an investigational agent or using an investigational device.
- Has undergone major surgery within 30 days of Study Day 1.
- Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
- Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
- History of myocardial infarction, unstable angina, congestive heart failure within 12 months prior to day 1 of study treatment.
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
- Has received a live virus vaccine within 30 days of the planned first dose of study therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Part 1 cohort 1
Subjects receive cadonilimab combination chemotherapy(SOX) neoadjuvant therapy 3 cycles.
|
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
Oral,Specified dose on specified days
|
|
Experimental: Part 1 cohort 2
Subjects receive cadonilimab combination chemotherapy(SOX) and AK117 neoadjuvant therapy 3 cycles.
|
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
Oral,Specified dose on specified days
|
|
Experimental: Part 2 cohort 1
Subjects receive cadonilimab combination chemotherapy(FLOT) neoadjuvant therapy 4 cycles.
|
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
|
|
Experimental: Part 2 cohort 2
Subjects receive cadonilimab combination chemotherapy(FLOT) and AK117 neoadjuvant therapy 4 cycles.
|
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence and severity of adverse events (AE), rate of surgical delays, abnormal laboratory findings of clinical significance
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Pathological complete response (pCR) rates
Time Frame: Up to approximately 2 years
|
pCR is defined the 0% residual viable tumor cells in the primary tumor and sampled lymph nodes
|
Up to approximately 2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ADA
Time Frame: Up to approximately 2 years
|
Number of subjects with detectable anti-drug antibodies (ADA).
|
Up to approximately 2 years
|
|
Major pathological response(MPR) rates
Time Frame: Up to approximately 2 years
|
MPR is defined the ≤10% residual viable tumor cells in the primary tumor and sampled lymph nodes
|
Up to approximately 2 years
|
|
Tumor regression grade(TRG)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
R0 resection rate
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Tumor descending stage rate
Time Frame: Up to approximately 2 years
|
Proportion of subjects whose tumor TNM stage decreased from baseline before surgery
|
Up to approximately 2 years
|
|
ORR
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
EFS
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
OS
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
PK
Time Frame: Up to approximately 2 years
|
Serum drug concentrations of cadonilimab and/or AK117 in individual subjects at different time points
|
Up to approximately 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Adenocarcinoma
- Esophageal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Docetaxel
- Fluorouracil
- Oxaliplatin
- Tegafur
Other Study ID Numbers
Other Study ID Numbers
- AK104-219
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.